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Treatment of the patients with abnormal cervical cytology: 
a “see-and-treat” versus three-step strategy
HanByoul Cho, Jae-Hoon Kim
Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Objective: To examine the correlation between cervical cytology and final histological results in patients who have 
undergone loop electrosurgical excision procedure (LEEP) with or without colposcopy-directed biopsy.
Methods: A retrospective review was performed of 829 patients who underwent LEEP for abnormal cervical cytology 
at Gangnam Severance Hospital between January 2004 and December 2008. Patients were classified to three groups 
according to cervical cytology and also divided into two groups based on the treatment they received: see-and-treat 
group and the standard three-step group. Final histological results were compared for the each study group.
Results: There were no differences in the final histological results between see-and-treat and three-step group in 
patients with high-grade squamous intraepithelial lesions (HSIL) cytology (N=523) (p=0.71). However, in patients 
with low-grade squamous intraepithelial lesions (LSIL)/atypical squamous cells of undetermined significance (ASCUS) 
(N=257) or normal cytology (N=49), the final histological results were significantly different between see-and-treat 
and three-step group (p＜0.001) and the rate of overtreatment was significantly higher in the see-and-treat group (p
＜0.001). 
Conclusion: A see-and-treat protocol may be a viable alternative only in patients with HSIL cytology if colposcopic 
impression is suggestive of cervical intraepithelial neoplasia (CIN) 2 or 3 lesions.
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INTRODUCTION
Cervical cancer is the second most common cancer in wom-
en worldwide, with approximately 440,000 cases reported 
annually.1 Cervical cancer has been the most common cancer 
among Korean women, but a 2002 report indicated that the 
number of women with cervical cancer has decreased to less 
than 10% of the total number of cancers in women, reducing 
the annual rate of cervical cancer to 20 cases per 100,000 
women. However, approximately 5,000 new cases still devel-
op in Korea annually, and about 1,300 of these patients die of 
the disease.2
One problem with cervical cancer screening is the cost and 
time that is required for evaluation, treatment, and fol-
low-up.3-7 Under the standard three-step treatment, the ap-
pearance of high-grade squamous intraepithelial lesions 
(HSIL) on a Papanicolaou (Pap) smear usually leads to a cer-
vical biopsy guided by colposcopy. If the histological result of 
the biopsy is cervical intraepithelial neoplasia (CIN) 2 or 3, 
loop electrosurgical excision procedure (LEEP) or conization 
is performed. It is cost-ineffective and time-consuming due to 
all of the visits required for diagnosis, treatment, and out-
patient follow-up. Once a patient has an abnormal cervical cy-
tology, she has to visit an outpatient clinic once for a colpo-
scopy-directed biopsy, and once again for treatment. In addi-
tion, if the colposcopy-directed biopsy cannot be performed in 
the appropriate area, it can affect the prognosis of the patient 
and make the reliability of biopsy controversial. Even further, 
patients may suffer from emotional anxiety while waiting for 
the results of the biopsy. These factors have led to new and al-
ternative strategies for evaluating and treating abnormal cer-
vical cytology. 
When a see-and-treat is applied, LEEP can be performed im-
mediately without biopsy if CIN2/3 is suspected at colpo-
scopic examination. The see-and-treat provides an oppor-
tunity for patients to be diagnosed and treated in a single out-
patient visit. This approach should reduce overall costs, the 
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Table 1. General characteristics of study populations
Variables
See-and-treat
(N=432)
Three-step
(N=397)
Age, means
Pap smear, no. (%)
Normal
LSIL/ASCUS
HSIL
HPV test positive, no. (%)
Normal
LSIL/ASCUS
HSIL
Final histology, no. (%)
Negative
CIN1
CIN2
CIN3
SCC
40.6
 
16 (3.7)
129 (29.8)
287 (66.4)
 
1/16 (6.2)
41/129 (31.8)
262/287 (91.3)
 
126 (29.2)
45 (10.4)
58 (13.4)
183 (42.4)
20 (4.6)
38.3
 
33 (8.3)
128 (32.2)
236 (59.5)
 
2/33 (6.1)
44/128 (34.4)
209/236 (88.6)
 
61 (15.4)
36 (9.1)
66 (16.6)
214 (53.9)
20 (5.0)
LSIL: low-grade squamous intraepithelial lesions, ASCUS: atypical 
squamous cells of undetermined significance, HSIL: high-grade 
squamous intraepithelial lesion, HPV: human papilloma virus, CIN: 
cervical intraepithelial neoplasia, SCC: squamous cell carcinoma.
number of hospital visits, noncompliance, and the patient 
anxiety.8,9 Although advantageous in certain patient pop-
ulations, this strategy may result in overtreatment because of 
the low specificity of Pap smears.
In this study, we evaluated the feasibility of a see-and-treat 
by dividing patients with abnormal cytology who have under-
gone LEEP into two study groups, based on whether they were 
treated with or without colposcopy-directed biopsy. The final 
histological results of the two study groups were compared.
MATERIALS AND METHODS
1. Study subjects
We conducted a retrospective review of the medical records 
of 1,011 patients who underwent LEEP at the Department of 
Obstetrics and Gynecology at Gangnam Severance Hospital 
from January 2004 to December 2008. Each patient with a di-
agnosis of abnormal cervical cytology initially underwent col-
poscopic examination. However, colposcopic examination 
was also performed in the patients with normal cytology when 
the patient needed further evaluation due to continuous de-
tection of the human papillomavirus (HPV), or the fear of 
cancer. “Continuous detection of the HPV” was defined as 
having two or more HPV DNA positive tests with more than 
6 months interval between HPV tests. Study subjects were 
divided into two groups based on the treatment they received: 
see-and-treat group (If the colposcopic impression was CIN 
2/3, LEEP was immediately performed without processing a 
colposcopy-directed biopsy), and the standard three-step group 
(If there appeared a suspected lesion of CIN2/3 at colposcopic 
examination, colposcopy-directed biopsy was performed. All 
patients diagnosed with CIN 2/3 in the colposcopy-directed 
biopsy subsequently received LEEP procedure). We only in-
cluded the cases diagnosed with CIN2/3 by colposcopy-directed 
biopsy, and the cases with CIN1 or negative histology by col-
poscopy-directed biopsy were excluded. The patients with 
glandular cell abnormalities in cervical cytology and a history 
of cervical dysplasia/cancer were also excluded. The patients 
were randomly assigned to one of two treatment protocols, 
and the decision towards LEEP was not influenced by the ex-
tent of cytologic findings.
Colposcopic examination of the cervix was performed after 
application of 5% acetic acid solution to the ectocervix. In or-
der to have an adequate colposcopic examination, the entire 
transformation zone, if present, was fully visualized. The 
LEEP procedure was performed with an electrosurgical unit 
(Surgitron® FFPF EMC, Ellman International INC., Hewlett, 
NY, USA), using an appropriate sized wire loop (8, 15, 20, or 
25 mm loop bayonet electrodes). The size of the wire loop was 
chosen on the basis of the colposcopic findings during the 
procedure. Surgical specimens were stored in a 10% formalin 
solution and submitted to the Department of Pathology for 
histopathologic evaluation. Abnormal Pap smears are re-
viewed by a senior pathologist. All colposcopic examinations 
and LEEP were performed at our hospital by one gynecologic 
oncology specialist. The classification of cervical cytology was 
performed according to the 2001 Bethesda system,10 and the 
final histological results were reviewed by two gynecologic 
pathologists. This study was approved by the Institutional 
Review Board (IRB) of Gangnam Severance Hospital.
2. Clinical data collection
For the study subjects, cervical cytology, colposcopy-directed 
biopsy, and final histology were recorded. To determine the 
human papillomavirus (HPV) infection rate in the study group, 
Hybrid Capture® 2 (HC2) test results were also reviewed. 
3. Statistical analysis
The final histological results were classified as Negative 
(absence of CIN), CIN1, CIN2, CIN3, and squamous cell car-
cinoma (SCC), and then analyzed using SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA). Comparisons between the groups 
were evaluated by chi-square (χ2) test, and p＜0.05 was con-
sidered to be statistically significant. In addition, the final his-
tological results were divided into two groups: 1) overtreat-
ment group (final histology ≤CIN1), and 2) correct treat-
ment group (final histology ≥CIN2), and the rate of agree-
ment between the initial and final diagnoses in the see-and- 
treat and three-step group was compared.
RESULTS
A total of 829 cases were finally included in this study. The 
clinical characteristics of the study subjects are listed in Table 1. 
There were 287 HSIL, 129 low-grade squamous intraepithelial 
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Table 2. Histological results of LEEP specimens in patients with 
HSIL cytology*
Histology
See-and-treat (N=287) Three-step (N=236)
p-value
no. (%)
Negative
CIN1
CIN2
CIN3
SCC
38 (13.2) 
14 (4.9) 
49 (17.1) 
167 (58.2) 
19 (6.6) 
30 (12.7) 
14 (5.9)
21 (9.0) 
152 (64.4) 
19 (8.0) 
0.71
LEEP: loop electrosurgical excision procedure, HSIL: high-grade 
squamous intraepithelial lesion, CIN: cervical intraepithelial neo-
plasia, SCC: squamous cell carcinoma.
*All patients had HSIL on Pap smear and high-grade lesions (≥CIN2)
on colposcopy-directed biopsy or suspected lesions equivalent of 
≥CIN2 on colposcopy.
Table 3. Histological results of LEEP specimens in patients with 
LSIL/ASCUS cytology*
Histology
See-and-treat (N=129) Three-step (N=128)
p-value
no. (%)
Negative
CIN 1
CIN 2
CIN 3
SCC
81 (62.8)
25 (19.4)
7 (5.4)
15 (11.6)
1 (0.8)
28 (21.9)
19 (14.8)
31 (24.2)
49 (38.3)
1 (0.8)
＜0.001
LEEP: loop electrosurgical excision procedure, LSIL: low-grade squ-
amous intraepithelial lesion, ASCUS: atypical squamous cells of un-
determined significance, CIN: cervical intraepithelial neoplasia, SCC:
squamous cell carcinoma.
*All patients had LSIL/ASCUS on Pap smear and high-grade lesions 
(≥CIN2) on colposcopy-directed biopsy or suspected lesions equi-
valent of ≥CIN2 on colposcopy.
Table 4. Histological results of LEEP specimens in patients with 
normal cytology*
Histology
See-and-treat (N=16) Three-step (N=33)
p-value
no. (%)
Negative
CIN1
CIN2
CIN3
SCC
7 (43.7)
6 (37.5)
2 (12.6)
1 (6.2)
0 (0)
3 (9.1)
3 (9.1)
14 (42.4)
13 (39.4)
0 (0)
＜0.001
LEEP: loop electrosurgical excision procedure, CIN: cervical intra-
epithelial neoplasia, SCC: squamous cell carcinoma.
*All patients had normal Pap smear and high-grade lesions (≥CIN2)
on colposcopy-directed biopsy or suspected lesions equivalent of 
≥CIN2 on colposcopy.
Fig. 1. The rate of high-grade lesions (≥CIN2) in final histology ac-
cording to treatment modalities. There were no significant differences
in the rate of final diagnosis of more than CIN2 between see-and-treat
and three-step group in patients with HSIL cytology (p=0.51), while 
there were significant differences in LSIL/ASCUS and normal cytol-
ogy cases (p＜0.001).
CIN: cervical intraepithelial neoplasia, SCC: squamous cell carcinoma,
HSIL: high-grade squamous intraepithelial lesions, LSIL: low-grade 
squamous intraepithelial lesions, ASCUS: atypical squamous cells of 
undetermined significance.
lesions (LSIL)/atypical squamous cells of undetermined sig-
nificance (ASCUS), and 16 normal cervical cytology cases in 
the see-and-treat group and 236 HSIL, 128 LSIL/ASCUS, and 
33 normal cytology cases in the three-step group. The mean 
ages were 40.6±9.8 years for see-and-treat group and 38.3± 
9.2 years for three-step group. There were no significant age 
differences between the groups (p=0.19). In the HC2 test, 
HPV DNA positivity was 6.1% in normal cytology, 33.1% in 
LSIL/ASCUS cytology, and 90.1% in HSIL cytology. There 
was no significant difference in HC2 positivity between the 
see-and-treat and three-step group (p=0.76).
The results of the final histological tests of 523 patients with 
HSIL cytology who were treated either by the see-and-treat or 
three-step protocol are presented in Table 2. There was no sig-
nificant difference in final histology between the two study 
groups. The final histological results of 257 patients who re-
ceived LEEP despite LSIL/ASCUS on cervical cytology are 
shown in Table 3. Patients in the three-step group were sig-
nificantly more likely to have high-grade histological results 
(≥CIN2) (p＜0.001). In patients with normal cervical cytol-
ogy, the final histological results showing high-grade lesions 
(≥CIN2) were also significantly more prevalent in the three- 
step group (p＜0.001) (Table 4).
Fig. 1 demonstrates the rate of agreement between the cer-
vical cytology and final histology in the study groups. In pa-
tients with HSIL cytology, the final histological diagnosis was 
in agreement with initial cytologic diagnosis in 81.9% (235 
out of 287 cases) in the see-and-treat group, and 81.4% (192 
out of 236 cases) in the three-step group. The rate of agree-
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ment between the two study groups was similar (p=0.51). 
However, in patients with LSIL/ASCUS and normal cervical 
cytology, the rate of agreement was 17.8% (23 out of 129 cas-
es) and 18.8% (3 out of 16 cases), respectively, in the see-and- 
treat group, and 63.3% (81 out of 128 cases) and 81.8% (27 
out of 33 cases), respectively, in the three-step group. There 
were significant differences in the rate of agreement between 
the initial and final diagnosis (p＜0.001).
DISCUSSION
See-and-treat approaches are relatively new and have been 
surrounded with controversy since their introduction. One of 
the controversies is due to the overtreatment which is partly 
based on the fact that colposcopy is not a perfect diagnostic 
test. Data from the ALTS (ASCUS/LSIL Triage Study) trial 
showed only 15% of women referred with ASCUS cytology 
had biopsy-proven CIN2/3 (85% over diagnosis). Similarly, 
women with LSIL cytology had a 25% rate of CIN2/3 (75% 
over diagnosis).11,12
The risk of overtreatment, or unnecessary treatment, is one 
of the main criticisms of the see-and-treat approach. The ef-
fectiveness of see-and-treat depends on colposcopic im-
pression. Although most studies have found colposcopy to be 
reasonably accurate compared with cervical pathological diag-
nosis,13 colposcopy is subject to intra- and interobserver vari-
ability, and potentially leads to overtreatment. Thus, patients 
may be unnecessarily exposed to bleeding and infection, which 
are the most common complications of the LEEP procedure. 
Therefore, we recommend that see-and-treat strategy is only 
appropriate when an experienced colposcopist can differ-
entiate low-grade from high-grade lesions, and the quality of 
colposcopic practice should be improved by setting appro-
priate standards.
Recently, strategies have limited the see-and-treat protocol 
to only patients with HSIL cervical cytology. To decrease the 
possibility of overtreatment, patients must have a high proba-
bility of having CIN2/3 before undergoing the see-and-treat 
protocol. The use of see-and-treat strategy in a patient pop-
ulation with an HSIL cervical cytology has been shown to de-
crease overtreatment. Irvin and co-workers reported on a trial 
that included patients with a Pap smear and colposcopic diag-
nosis of HSIL.14 Overtreatment was 18% if the threshold in-
cluded patients with mild dysplasia and those with negative 
pathology results. Overtreatment decreased to 4% when the 
threshold was lowered to include only patients with negative 
pathology results.
Although there are some controversies in the see-and-treat 
strategy, the necessity of colposcopy-directed biopsy is also 
controversial. In 2006, Byrom et al.15 performed biopsies 
guided by colposcopy in the area that was thought to be the 
most appropriate in lesions of 170 patients with high-grade 
cytology or colposcopic findings. They simultaneously per-
formed LEEP and compared their histological results. 
Approximately 70% of the histological results of colpo-
scopy-directed biopsies concurred with the final histological 
results obtained by LEEP and showed a tendency to under-
evaluate the disease. Another study also indicated the dis-
advantages of colposcopy-directed biopsy.16 They suggested 
that it did not lower the rate of false positives and therefore 
could not improve the accuracy of diagnosis. It also delayed 
the treatment, resulting in increased emotional anxiety in 
patients.
In the current study, we compared the final histological re-
sults of see-and-treat protocol with those of the standard 
three-step protocol. In our data set, the rate of agreement be-
tween initial and final diagnoses was not significantly different 
only in the HSIL cytology cases, indicating that the addition of 
a colposcopy-directed biopsy does not reduce the ratio of 
overtreatment, and has a limited predictive value for the final 
histological result after LEEP in patients with HSIL cytology. 
In the HSIL cytology cases, 19 out of 287 patients (6.6%) in 
the see-and-treat group were diagnosed with invasive carcino-
ma after LEEP, as shown in Table 2. All patients with invasive 
carcinoma were immediately treated according to National 
Cancer Comprehensive Network (NCCN) clinical practice 
guidelines the next day.
In the LSIL/ASCUS, or normal cytology cases, there were 
more cases of correct treatment (final histology ≥CIN2) in 
the three-step group (63.3% in LSIL/ASCUS cytology and 
81.8% in normal cytology) than in the see-and-treat group 
(17.8% in LSIL/ASCUS cytology and 18.8% in normal cytol-
ogy ) (p＜0.001). As a result, overtreatment was much more 
prevalent in the see-and-treat group in patients with LSIL/ 
ASCUS or normal cytology. Therefore, for patients with LSIL/ 
ASCUS or normal cytology, colposcopy-directed biopsy be-
fore LEEP can be considered effective. One literature indicates 
that 5% to 17% of ASCUS and 15% to 30% of LSIL found on 
Pap smears have associated high-grade dysplasia. In contrast, 
70% to 75% of HSIL test results are associated with severe 
dysplasia and the reproducibility of HSIL is far greater than 
that of ASCUS.17 Therefore, we did not believe that it was ap-
propriate to perform a LEEP without colposcopy-directed bi-
opsy in patients with low-grade lesions found on cervical 
cytology.
The see-and-treat strategy was also associated with the low-
est cost in the management of HSIL cytology result, producing 
a 41% cost reduction compared with conventional manage-
ment of the patients with HSIL.18 In addition, the patient’s 
anxiety may be relieved by assurance from the physician that 
the lesion has been found and destroyed completely, and will 
be assessed histologically.9 In surveys based on confidential 
questionnaires, patients’ satisfaction with the see-and-treat 
strategy was shown to be acceptable.19,20
The current study has several potential limitations that must 
be considered in the interpretation. One limitation is the ret-
rospective nature of this study, in which the possibility of se-
lection bias increases. Another limitation is the small number 
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of study subjects. Despite these potential limitations, we re-
port that the see-and-treat protocol may be an effective strat-
egy in patients with HSIL on cervical cytology and suggestive 
of CIN2/3 after colposcopy. However, colposcopy-directed bi-
opsy must be performed before LEEP in patients with 
LSIL/ASCUS or normal cytology for more accurate diagnosis 
and prevention of overtreatment.
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